Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ozurdex

PreclinicalSmall molecule

Ozurdex is one of 36 small molecule programs targeting Fibrosis. It is currently in Preclinical.

2

Indications

21

Total Trials

1

Active Trials

35

Competitors

Pipeline

Status by Indication[3][1]

Indication

FibrosisActive, not recruiting

Epiretinal MembraneActive, not recruiting

FibrosisPreclinical

Active, not recruiting

Epiretinal MembranePreclinical

Active, not recruiting

Competition

Competitive Landscape

35 competitors in Fibrosis

#DrugCompanyPhaseTrials

Cellcept

Vemlidy

Lexiscan

Neoral

Esbriet

LLegacy Health System

Glucophage

Rayos

RRoxane Laboratories

Rapamune

PPrism Pharmaceuticals

Actemra

Viagra

VViatris Specialty LLC

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Diabetic Macular Edema6 trials

Combination OZURDEX® & LUCENTIS® vs. OZURDEX® Monotherapy in Incomplete-Responders With Diabetic Macular Edema

Terminated·NNorth Toronto Eye Care Laser and Eye Specialists·Phase 4·NCT02684084·5 enrolled

Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification

Completed·BBay Area Retina Associates·Phase 4·NCT03832179·16 enrolled

Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study)

Completed·TThe Cleveland Clinic·Phase 4·NCT01613716·30 enrolled

Show 3 more trials

Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema

Withdrawn·PPradeepa Yoganathan·Phase 2·NCT03629210

Retrospective Trial on the Efficacy and Safety of Intravitreal Ozurdex in Patients With Diabetic Macular Edema.

Completed·AAssociation for Innovation and Biomedical Research on Light and Image··NCT02121197·321 enrolled

Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema

Completed·—·Phase 4·NCT02036424·45 enrolled

Retinal Vein Occlusion4 trials

Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)

Completed·LLong Island Vitreoretinal Consultants·N/A·NCT01231633·27 enrolled

Evaluation of OZURDEX® in Patients With Macular Edema Secondary to Retinal Vein Occlusion in China

Completed· AbbVie logo

AbbVie·Phase 4·NCT03908307·150 enrolled

Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.

Completed·RRetina Macula Institute·Phase 3·NCT01449682·10 enrolled

Show 1 more trial

Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion

Unknown status·VValley Retina Institute·Phase 4·NCT01827722·45 enrolled

Fibrosis1 trial

Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases

Terminated·JJohns Hopkins University··NCT02688309·44 enrolled

Macular Degeneration1 trial

OZURDEX in Age Related Macular Degeneration as Adjunct to Ranibizumab

Completed·MMcMaster University·Phase 2·NCT01243086·10 enrolled

Dexamethasone1 trial

Dexamethasone-Implant for the Treatment of Macula Edema Due to Irvine Gass Syndrome

Completed·LLudwig-Maximilians - University of Munich··NCT01945892·23 enrolled

8 more indications

Uveal Melanoma1 trial

Dexamethasone Intravitreal Implant for Treatment of Macular Edema After Plaque Radiotherapy of Uveal Melanoma

Terminated·AArman Mashayekhi·Phase 2·NCT01471054·6 enrolled

Monotherapy1 trial

Ozurdex Monotherapy Trial

Withdrawn·OOttawa Hospital Research Institute·Phase 4·NCT05101928

Patient Preference1 trial

Patient Preferences on Same-day Bilateral Intravitreal Dexamethasone Injections

Recruiting·RRigshospitalet, Denmark··NCT06894017·200 enrolled

Diabetic Macular Oedema1 trial

Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema

Completed·UUniversity of Sydney·Phase 2·NCT01787669·19 enrolled

Treatment Failure1 trial

Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF

Terminated·RRetina Research Institute, LLC·N/A·NCT01946399·10 enrolled

Trial1 trial

One Year Trial Evaluating Safety of Ozurdex With Eylea

Completed·TTexas Retina Associates·Phase 4·NCT03984110·50 enrolled

Epiretinal membrane1 trial

A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Surgery for Epiretinal Membranes

Unknown status·SSunnybrook Health Sciences Centre·N/A·NCT01701518·15 enrolled

Randomized Controlled Trial1 trial

Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed by Intraoperative OCT (the VIDEO Study): Study Protocol for a Randomized Controlled Trial

Unknown status·TTianjin Medical University Eye Hospital·Phase 4·NCT05990829·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for Ozurdex. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ozurdex compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ozurdex. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: AbbVie

Related News